Journal
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
Volume 22, Issue 7, Pages 413-425Publisher
SPRINGER
DOI: 10.1007/s11910-022-01198-3
Keywords
Leptomeningeal disease; Antibody-drug conjugate; Circulating tumor cells; Circulating tumor DNA; Intrathecal treatment; Tyrosine kinase inhibitors
Categories
Ask authors/readers for more resources
The purpose of this review is to provide an overview of leptomeningeal disease (LMD), a rare late complication of systemic cancer, and discuss recent research findings and clinical practice trends in its diagnosis and treatment. Improved molecular diagnostic tools are being developed to enhance the detection of LMD. Targeted and CNS-penetrant therapeutics have shown promise in improving survival rates, but more clinical trials are needed.
Purpose of Review Leptomeningeal disease (LMD) is a rare, late complication of systemic cancer and is associated with significant neurological morbidity and high mortality. Here we provide an overview of this condition, summarizing key recent research findings and clinical practice trends in its diagnosis and treatment. We also review current clinical trials for LMD. Recent Findings Improved molecular diagnostic tools are in development to enable more sensitive detection of LMD, including circulating tumor cells and circulating tumor DNA. The use of targeted and CNS-penetrant therapeutics has shown survival improvements with tyrosine kinase inhibitors, antibody-drug conjugates, and select chemotherapy. However, these studies have primarily been phase I/II and retrospective analyses. There remains a dearth of clinical trials that include LMD patients. Summary The combination of patient-specific molecular information and novel therapeutic approaches holds significant promise for improving outcomes in patients with LMD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available